Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Cardiol Therapeutics (CRDL) over the last 5 years, with Dec 2024 value amounting to $13.8 million.

  • Cardiol Therapeutics' Cash from Financing Activities fell 100.57% to -$10,615 in Q3 2022 from the same period last year, while for Sep 2022 it was $47.0 million, marking a year-over-year change of. This contributed to the annual value of $13.8 million for FY2024, which is 33628.33% up from last year.
  • Latest data reveals that Cardiol Therapeutics reported Cash from Financing Activities of $13.8 million as of FY2024, which was up 33,628.33% from -$41,043 recorded in FY2023.
  • Over the past 5 years, Cardiol Therapeutics' Cash from Financing Activities peaked at $74.6 million during FY2021, and registered a low of -$41,484 during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$41,043 (2023), whereas its average is $4.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 100.06% in 2022, then soared by 33,628.33% in 2024.
  • Over the past 5 years, Cardiol Therapeutics' Cash from Financing Activities (Yearly) stood at $12.2 million in 2020, then spiked by 512.95% to $74.6 million in 2021, then tumbled by 100.06% to -$41,484 in 2022, then rose by 1.06% to -$41,043 in 2023, then spiked by 33,628.33% to $13.8 million in 2024.